OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
076758

Zhong Ji Longevity Science Group Ltd

Consumer LendingVerified

Zhong Ji Longevity Science Group Ltd maintains a strong liquidity position with a current ratio of 6.59, indicating ample short-term assets to cover liabilities. The company holds HKD 24.3 million in cash and equivalents, representing 4.9% of total assets, and has minimal long-term debt of HKD 5.6 million. This liquidity profile supports operational flexibility but does not offset the negative returns on equity and assets. The company's profitability is weak, with a return on equity of -4.21% and a return on assets of -3.35%, both significantly below the industry median for consumer lending firms. Operating income was negative at HKD -12.5 million, and net income was HKD -16.8 million, reflecting challenges in cost control and revenue generation. Zhong Ji Longevity Science Group Ltd operates through five segments, with the Money Lending segment likely representing the largest revenue contributor. However, the company does not disclose segment revenue breakdowns, limiting visibility into geographic or product concentration. The company's exposure to the longevity science and financial services markets may be sensitive to regulatory and macroeconomic shifts. The company's revenue growth trajectory is unclear, as the most recent reported revenue of HKD 161.8 million represents a decline from the analyst-estimated HKD 734 million in prior periods. This discrepancy suggests potential volatility or reporting inconsistencies in revenue recognition. Risk factors include low liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt-to-equity ratio of 0.01 suggests conservative leverage, but the negative net income raises concerns about long-term sustainability. No dilution adjustments were applied in the valuation model. Recent filings and transcripts do not indicate material events affecting the company's operations or financial position. The absence of significant capital expenditures or R&D investments in the financial snapshot suggests a focus on maintaining existing operations rather than growth.

30-day price · 0767-0.12 (-24.0%)
Low$0.36High$0.52Close$0.38As of22 May, 00:00 UTC
Profile
CompanyZhong Ji Longevity Science Group Ltd
Ticker0767.HK
SectorFinancials
BusinessBanking & Investment Services
Industry groupBanking & Investment Services
IndustryConsumer Lending
AI analysis

Business. Zhong Ji Longevity Science Group Ltd operates in the longevity science and money lending sectors, generating revenue through medical testing, biological products, member services, and consumer lending.

Classification. Zhong Ji Longevity Science Group Ltd is classified under the Financials sector, Banking & Investment Services business sector, and Consumer Lending industry with 92% confidence.

Zhong Ji Longevity Science Group Ltd maintains a strong liquidity position with a current ratio of 6.59, indicating ample short-term assets to cover liabilities. The company holds HKD 24.3 million in cash and equivalents, representing 4.9% of total assets, and has minimal long-term debt of HKD 5.6 million. This liquidity profile supports operational flexibility but does not offset the negative returns on equity and assets. The company's profitability is weak, with a return on equity of -4.21% and a return on assets of -3.35%, both significantly below the industry median for consumer lending firms. Operating income was negative at HKD -12.5 million, and net income was HKD -16.8 million, reflecting challenges in cost control and revenue generation. Zhong Ji Longevity Science Group Ltd operates through five segments, with the Money Lending segment likely representing the largest revenue contributor. However, the company does not disclose segment revenue breakdowns, limiting visibility into geographic or product concentration. The company's exposure to the longevity science and financial services markets may be sensitive to regulatory and macroeconomic shifts. The company's revenue growth trajectory is unclear, as the most recent reported revenue of HKD 161.8 million represents a decline from the analyst-estimated HKD 734 million in prior periods. This discrepancy suggests potential volatility or reporting inconsistencies in revenue recognition. Risk factors include low liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt-to-equity ratio of 0.01 suggests conservative leverage, but the negative net income raises concerns about long-term sustainability. No dilution adjustments were applied in the valuation model. Recent filings and transcripts do not indicate material events affecting the company's operations or financial position. The absence of significant capital expenditures or R&D investments in the financial snapshot suggests a focus on maintaining existing operations rather than growth.
Key takeaways
  • The company maintains strong liquidity but operates with negative returns on equity and assets.
  • Revenue volatility and lack of segment disclosure limit visibility into growth drivers.
  • Minimal leverage and no immediate dilution risk provide some stability.
  • The discrepancy between reported and analyst-estimated revenue raises questions about financial reporting consistency.
  • --
  • ## RATIONALES
  • ```json
  • {
Financial snapshot
PeriodHA-latest
CurrencyHKD
Revenue$161.8M
Gross profit$26.5M
Operating income-$12.5M
Net income-$16.8M
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets$499.9M
Total liabilities$102.3M
Total equity$397.6M
Cash & equivalents$24.3M
Long-term debt$5.6M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1$166.2M-$31.6M-$34.7M-$28.7M
FY-2$65.0M$6.8M$2.3M$9.9M
FY-3$89.7M$11.4M-$904.0k$3.9M
FY-4$61.1M$6.8M$6.1M$9.7M
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1$525.6M$373.4M
FY-2$509.3M$403.4M
FY-3$484.8M$393.8M
FY-4$517.5M$443.7M
PeriodOCFCapExFCFSBC
FY0
FY-1-$61.1M-$708.0k-$28.7M
FY-2$15.7M$0.00$9.9M
FY-3$12.0M-$1.0M$3.9M
FY-4-$41.2M-$889.0k$9.7M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$397.6M
Net cash$18.7M
Current ratio6.6
Debt/Equity0.0
ROA-3.4%
ROE-4.2%
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Banking · cohort 1 companies
Metric0767Activity
Op margin-7.7%27.8% medp25 11.0% · p75 56.0%bottom quartile
Net margin-10.4%30.4% medp25 30.4% · p75 30.4%bottom quartile
Gross margin16.4%63.4% medp25 42.7% · p75 94.6%bottom quartile
CapEx / revenue19.6% medp25 19.6% · p75 19.6%
Debt / equity1.0%590.5% medp25 317.2% · p75 863.7%bottom quartile
Observations
IR observations
Last actual EPS-571.00 HKD
Last actual revenue734,038,000 HKD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 13:06 UTC#8fde2dba
Market quoteclose HKD 0.38 · shares 0.64B diluted
no public URL
2026-05-09 10:52 UTC#bf1509c8
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 13:08 UTCJob: a869c776